TCRαβ/CD19清除或移植后环磷酰胺HLA不合造血干细胞移植治疗先天性免疫缺陷病的结局
该回顾性多中心EBMT注册研究纳入2010至2019年间接受首次HLA不合移植的306例先天性免疫缺陷病患儿,其中TCRαβ组167例、PTCY组139例。TCRαβ组3年总生存率78%高于PTCY组66%(P=0.013);PTCY组严重急性GVHD、肝静脉闭塞病、急性肾损伤及肺部并发症发生率更高,TCRαβ组腺病毒血症、原发植入失败及二次移植率更高。
要点
- TCRαβ组3年OS为78%,高于PTCY组的66%(P=0.013)。
- PTCY组严重急性GVHD累积发生率15%,高于TCRαβ组的6%(P=0.007)。
- TCRαβ组腺病毒血症18.3%、原发植入失败10%、二次移植17.4%,均高于PTCY组。
核心结论
- TCRαβ与PTCY两种方法均为先天性免疫缺陷病患者的合适选择,但各有不同的优势和结局。
研究设计与样本
- 通过EBMT注册开展的回顾性多中心研究,纳入2010至2019年间接受首次HLA不合供者移植的306例先天性免疫缺陷病患儿。
- TCRαβ组167例,PTCY组139例;造血干细胞移植中位年龄1.2岁(范围0.03-19.6岁)。
主要发现
- 3年总生存率TCRαβ组78%(95%CI 71-84) vs PTCY组66%(57-74),P=0.013。
- 移植前疾病负担评分(HR 2.27;95%CI 1.07-4.80,P=0.032)和非白消安/曲奥舒凡预处理(HR 3.12;95%CI 1.98-4.92,P<0.001)是总生存不良的独立预测因素。
- 3年无事件生存率TCRαβ组58%(50%-66%) vs PTCY组57%(48%-66%),P=0.804。
- 严重急性GVHD累积发生率PTCY组15%(9%-21%) vs TCRαβ组6%(2%-9%),P=0.007;慢性GVHD两组差异无统计学意义(PTCY 11%,6%-17%;TCRαβ 7%,3%-11%,P=0.173)。
- 3年无GVHD无事件生存率TCRαβ组53%(44%-61%) vs PTCY组41%(32%-50%),P=0.080;PTCY组肝静脉闭塞病(14.4% vs 4.9%,P=0.009)、急性肾损伤(12.7% vs 4.6%,P=0.032)及肺部并发症(38.2% vs 24.1%,P=0.017)发生率更高;TCRαβ组腺病毒血症(18.3% vs 8.0%,P=0.015)、原发植入失败(10% vs 5%,P=0.048)及二次移植(17.4% vs 7.9%,P=0.023)更高。
临床怎么用
- 原文结论认为TCRαβ与PTCY两种方法均为先天性免疫缺陷病患者的合适选择,但各有不同的优势和结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HLA-mismatched transplants with either in vitro depletion of CD3+ T-cell receptor (TCR)αβ/CD19 (TCRαβ) cells or in vivo T-cell depletion using posttransplant cyclophosphamide (PTCY) have been increasingly used for patients with inborn errors of immunity (IEIs). We performed a retrospective multicenter study via the EBMT registry on 306 children with IEIs undergoing their first transplant between 2010 and 2019 from an HLA-mismatched donor using TCRαβ (n = 167) or PTCY (n = 139). The median age for hematopoietic stem cell transplantation (HSCT) was 1.2 years (range, 0.03-19.6 years). The 3-year overall survival (OS) was 78% (95% confidence interval (CI), 71-84) after TCRαβ and 66% (57-74) after PTCY (P = .013). Pre-HSCT morbidity score (hazard ratio [HR], 2.27; 1.07-4.80, P = .032) and non-busulfan/treosulfan conditioning (HR, 3.12; 1.98-4.92, P < .001) were the only independent predictors of unfavorable OS. The 3-year event-free survival (EFS) was 58% (50%-66%) after TCRαβ and 57% (48%-66%) after PTCY (P = .804). The cumulative incidence of severe acute graft-versus-host disease (GvHD) was higher after PTCY (15%, 9%-21%) than TCRαβ (6%, 2%-9%, P = .007), with no difference in chronic GvHD (PTCY, 11%, 6%-17%; TCRαβ, 7%, 3%-11%, P = .173). The 3-year GvHD-free EFS was 53% (44%-61%) after TCRαβ and 41% (32%-50%) after PTCY (P = .080). PTCY had significantly higher rates of veno-occlusive disease (14.4% vs TCRαβ 4.9%, P = .009), acute kidney injury (12.7% vs 4.6%, P = .032), and pulmonary complications (38.2% vs 24.1%, P = .017). Adenoviremia (18.3% vs PTCY 8.0%, P = .015), primary graft failure (10% vs 5%, P = .048), and second HSCT (17.4% vs 7.9%, P = .023) were significantly higher in TCRαβ. In conclusion, this study demonstrates that both approaches are suitable options in patients with IEIs, although they are characterized by different advantages and outcomes.
引用
- Lum SH, Albert MH, Gilbert P, et al. Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Blood. 2024. PMID: 38669631. doi:10.1182/blood.2024024038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。